Kalaris Therapeutics (KLRS) Cash & Equivalents (2019 - 2026)
Kalaris Therapeutics' Cash & Equivalents came in at $43.17 million for Q2 2026, down 51.2% from $88.43 million a year earlier but up 25.4% from the prior quarter.
Powered by 
Analysis
Kalaris Therapeutics (KLRS) Cash & Equivalents (2019 - 2026) Analysis & Trends
At the end of FY2025, Kalaris Therapeutics' Cash & Equivalents was $98.05 million.
- Cash & Equivalents carries a five-year compound annual growth rate of -4.4% (FY2020 to FY2025).
- Going back by year, Cash & Equivalents was $1.64 million in FY2024 (-98.2%), $90.12 million in FY2023 (-15.1%), $106.09 million in FY2022 (-47.4%) and $201.66 million in FY2021 (+64.4%).
- The five-year range for quarterly Cash & Equivalents is $1.64 million (Q4 2024) to $243.19 million (Q3 2021).
- The fastest year-over-year change in Cash & Equivalents over five years came in Q2 2023 (growth of 177.0%), and the weakest in Q4 2024 (a decline of 98.2%).
- Business Quant data shows KLRS's Cash & Equivalents at $34.43 million (Q1 2026), $98.05 million (Q4 2025) and $42.39 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Kalaris Therapeutics | 64.27 Mn | 64.27 Mn | - | 43.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 43.17 Mn |
| Mar 31, 2026 | 34.43 Mn |
| Dec 31, 2025 | 98.05 Mn |
| Sep 30, 2025 | 42.39 Mn |
| Jun 30, 2025 | 88.43 Mn |
| Mar 31, 2025 | 100.97 Mn |
| Dec 31, 2024 | 1.64 Mn |
| Sep 30, 2024 | 1.91 Mn |
| Jun 30, 2024 | 6.24 Mn |
| Mar 31, 2024 | 5.23 Mn |
| Dec 31, 2023 | 90.12 Mn |
| Sep 30, 2023 | 95.63 Mn |
| Jun 30, 2023 | 196.95 Mn |
| Mar 31, 2023 | 115.70 Mn |
| Dec 31, 2022 | 106.09 Mn |
| Sep 30, 2022 | 123.83 Mn |
| Jun 30, 2022 | 71.09 Mn |
| Mar 31, 2022 | 100.21 Mn |
| Dec 31, 2021 | 201.66 Mn |
| Sep 30, 2021 | 243.19 Mn |
API Access
Kalaris Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=KLRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "KLRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=KLRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();